Nuclear Medicine in Belgium

14 – 15 Oct 2026 | Suarlée, Belgium

HomeAgendaParticipantsMarketplace
Register
Register
Register

Telix Pharmaceuticals

Company

telixpharma.com/Melbourne, Australia

About

About Telix Pharmaceuticals Limited  

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).  

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) and Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) have been approved by the United States Food and Drug Administration (FDA)3,  and Illuccix is approved in multiple jurisdictions globally.  

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Application Domain

Nuclear Medicine

Core Business

CleanroomCMO/COMO

Technology

BiologicsImagingNuclear MedicineRadiodiagnosticRadioTheranosticRadio Isotopes ProductionRadio ChemistryParticules Accelerator

Therapeutic Area

Oncology

Representatives

Telix EMEA Radioisotopes Strategy Director

Telix Pharmaceuticals